December 6, 2019 10:53 AM EST

Antibiotic developer scores $50M from biotech billionaire; Biohaven's Alzheimer's drug passes futility test

ENDPOINTS

→ Antibiotic developer Summit Therapeutics has scored a cool $50 million in funding from biotech billionaire Robert Duggan — the former chief of Pharmacyclics, the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Antibiotic developer scores $50M from biotech billionaire; Biohaven's Alzheimer's drug passes futility test

ENDPOINTS

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

An­tibi­ot­ic de­vel­op­er scores $50M from biotech bil­lion­aire; Bio­haven's Alzheimer's drug pass­es fu­til­i­ty test

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Antibiotic developer scores $50M from biotech billionaire; Biohaven's Alzheimer's drug passes futility test